The group's principal activities are medical device research and development focused on thermal therapy technology. The group operates in the healthcare segment. Therapik®, the patented product of the group used for relief of pain and itch caused by insect stings and bites has been approved as a Class II medical device in Canada and the United States. The group's second product InterceptCS has been approved for marketing in Canada with the claim for prevention and relief of the symptoms of herpes labialis (cold sores) such as blistering, lesions, inflammation, and discomfort. Jenex holds the exclusive rights and patents to InterceptCS the hand-held thermal therapy device used for the prevention of cold sores. Worldwide markets including 22 Asian countries where licensing agreement for marketing Therapik® has been signed in 2004.
Therapik®, the first trademarked product of the company is patented in the United States, Canada, Australia and Europe to protect the technology.
